PT  - JOURNAL ARTICLE
AU  - Walsh, Kyle M.
AU  - Price, Mackenzie
AU  - Raleigh, David R.
AU  - Calabrese, Evan
AU  - Kruchko, Carol
AU  - Barnholtz-Sloan, Jill S.
AU  - Ostrom, Quinn T.
TI  - Elevated meningioma risk among individuals who are Non-Hispanic Black is strongest for grade 2-3 tumors and synergistically modified by male sex
AID  - 10.1101/2024.06.13.24308882
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.13.24308882
4099  - http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308882.short
4100  - http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308882.full
AB  - Background Meningioma risk factors include older age, female sex, and African-American race. There are limited data exploring how meningioma risk in African-Americans varies across the lifespan, interacts with sex, and differs by tumor grade.Methods The Central Brain Tumor Registry of the United States (CBTRUS) is a population-based registry covering the entire U.S. population. Meningioma diagnoses from 2004-2019 were used to calculate incidence rate ratios (IRRs) for non-Hispanic Black individuals (NHB) compared to non-Hispanic white individuals (NHW) across 10-year age intervals, and stratified by sex and by WHO tumor grade.Results 53,890 NHB individuals and 322,373 NHW individuals with an intracranial meningioma diagnosis were included in analyses. Beginning in young adulthood, the NHB-to-NHW IRR was elevated for both grade 1 and grade 2/3 tumors. The IRR peaked in the seventh decade of life regardless of grade, and was higher for grade 2/3 tumors (IRR=1.57; 95% CI: 1.46-1.69) than grade 1 tumors (IRR=1.27; 95% CI: 1.25-1.30) in this age group. The NHB-to-NHW IRR was elevated in females (IRR=1.17; 95% CI: 1.16-1.18) and further elevated in males (IRR=1.28; 95% CI: 1.26-1.30), revealing synergistic interaction between NHB race/ethnicity and male sex (PInteraction=0.001).Conclusions Relative to NHW individuals, NHB individuals are at elevated risk of meningioma from young adulthood through old age. NHB race/ethnicity conferred higher risk of meningioma among men than women, and higher risk of developing WHO grade 2/3 tumors. Results identify meningioma as a significant source of racial disparities in neuro-oncology and may help to improve preoperative predictions of meningioma grade.Competing Interest StatementJill S. Barnholtz-Sloan, Ph.D. is a full-time paid employee of the NIH/NCIFunding StatementFunding for CBTRUS was provided by the Centers for Disease Control and Prevention (CDC) Contract Number 75D30123P17556, the American Brain Tumor Association, Novocure, the Musella Foundation for Brain Tumor Research & Information, Inc., the National Brain Tumor Society, the Pediatric Brain Tumor Foundation, The Sontag Foundation, the Uncle Kory Foundation, the Josephine F. DeAngelis Memorial Fund, and the Zelda Dorin Tetenbaum Memorial Fund, as well as from private and in-kind donations. The research services of Jill S. Barnholtz-Sloan were provided by the Division of Cancer Epidemiology and Genetics of the NCI. Additional funding was provided by P30CA014236 (KMW) and P50CA190991 (KMW, QTO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved as an exempt protocol by the Duke University of Medicine IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in the present study are provided to the authors under contract with the CDC and are not publicly available